ResMed Inc. (ASX: RMD)
Australia
· Delayed Price · Currency is AUD | Market Cap | 41.69B |
| Revenue (ttm) | 6.64B |
| Net Income (ttm) | 1.44B |
| Shares Out | 1.47B |
| EPS (ttm) | 0.96 |
| PE Ratio | 28.91 |
| Forward PE | 23.87 |
| Dividend | 0.29 (1.01%) |
| Ex-Dividend Date | May 8, 2024 |
| Volume | 1,109,861 |
| Open | 28.50 |
| Previous Close | 28.33 |
| Day's Range | n/a |
| 52-Week Range | 21.14 - 34.27 |
| Beta | 0.69 |
| Analysts | n/a |
| Price Target | 34.42 (+21.28%) |
| Earnings Date | Aug 1, 2024 |
About ResMed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics... [Read more]
Financial Performance
In 2023, ResMed's revenue was $4.22 billion, an increase of 32.10% compared to the previous year's $3.20 billion. Earnings were $897.56 million, an increase of 89.16%.
Financial numbers in USD Financial StatementsNews
This Is What Whales Are Betting On ResMed
Deep-pocketed investors have adopted a bearish approach towards ResMed (NYSE: RMD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled thi...
ResMed Stock Is Down Because of GLP-1 Concerns. It Shouldn't Be.
Shares of ResMed, a maker of CPAP and other sleep-apnea airway machines, have dropped because of weight-loss developments. It's an overreaction.
ResMed cut at Oppenheimer after Eli Lilly’s tirzepatide sleep apnea data
Inspire Medical, ResMed decline following Lilly tirzepatide sleep apnea data
Inspire Medical Systems (INSP) and ResMed (RMD) see significant drops in trading after positive data on Eli Lilly's tirzepatide as a sleep apnea treatment. Read more here.
Why ResMed Shares Are Trading Lower Monday
ResMed, Inc. (NYSE: RMD) stock is trading lower Monday after Eli Lilly and Company (NYSE: LLY) released data from a clinical trial in regards to the treatment of sleep apnea . The Details: Lilly rel...
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
Full story available on Benzinga.com
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday.
Stocks making the biggest moves midday: ResMed, Affirm, Nvidia, Anheuser-Busch and more
These are the stocks posting the largest moves midday.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-14946233991-63319b97322e44d1967f699bb8eebcc9.jpg)
Top Stock Movers Now: Affirm, Nvidia, ResMed, and More
U.S. equities were mixed at midday Monday, June 24, 2024 as most sectors gained, but tech stocks lost ground.
Medical-device makers ResMed and Inspire slump after Lilly’s Zepbound trial shows benefits for sleep apnea
ResMed and Inspire Medical make devices that help patients with sleep apnea breathe better.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2126120470-4b91f7120b0a450f8c9a674333f424cc.jpg)
Why a Pair of Eli Lilly Clinical Trials Sent ResMed Stock Tumbling
Eli Lilly released results from a pair of clinical trials on Friday afternoon that showed the capability of its weight-loss drug Zepbound to reduce the severity of sleep apnea, potentially impacting R...
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again
ResMed stock and Inspire Medical Systems stock tumbled Monday after Eli Lilly said its weight-loss drug reduced sleep apnea events.
ResMed Stock Is Sinking. Blame Lillys Zepbound Trials for Sleep Apnea.
Biggest stock movers today: RXO, RMD, and more
ResMed sinks as drug trial spark Ozempic-style sell-off
New results from Eli Lilly’s weight-loss drug have traders reaching for the sell button, but analysts aren’t so sure.
ResMed, Philips under pressure as Eli Lilly seeks sleep indication for weight loss drug
4 Medical Product Stocks to Buy From a Recovering Industry
The Zacks Medical – Products industry's revenues are expected to continue its growth trajectory on the back of the recovery in demand for surgeries and procedures, new products and expansion into new ...
Insider Sale: CFO Brett Sandercock Sells Shares of ResMed Inc (RMD)
Insider Sale: CFO Brett Sandercock Sells Shares of ResMed Inc (RMD)
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the ...
$100 Invested In ResMed 20 Years Ago Would Be Worth This Much Today
ResMed (NYSE: RMD) has outperformed the market over the past 20 years by 7.11% on an annualized basis producing an average annual return of 15.03%. Currently, ResMed has a market capitalization of $3...
Derelict sites in Enniscorthy identified for compulsory purchase as council tackles housing shortages
As it continues its efforts to alleviate the housing crisis in the county, Wexford County Council (WCC) has provided details of its work bringing derelict properties back into the market. At the May m...
Here's How Much a $1000 Investment in ResMed Made 10 Years Ago Would Be Worth Today
How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors and...
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep ...
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024 Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott Marquis...
3 Hot Stocks to Buy That Still Look Undervalued
#Morningstar #HotStocks #StockInvesting These top-performing stocks have beaten the market in 2024 yet appear to have more room to run. 00:00 Introduction 00:43 Moderna MRNA 01:27 Hasbro HAS 02:06 Re...